

Correction: Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer

Mayadev J, Zamarin D, Deng W, *et al.* Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer. *Int J Gynecol Cancer* 2019;**30**:701–4. doi: 10.1136/ijgc-2019-001012

For this article, the authors noticed that their updated funding statement was incorrect. The correct funding statement is ‘This study was supported by National Institute of Health grants to NRG Oncology (1U10 CA180822) and NRG Operations (U10CA180868).’

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Int J Gynecol Cancer 2020;**30**:1266. doi:10.1136/ijgc-2019-001012corr2

